Status:
UNKNOWN
Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients
Lead Sponsor:
Jiarong Chen, MD
Conditions:
Pain
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The primary purpose of this study is to explore the significance of analgesic treatment for radiation-induced oral mucositis pain in patients with nasopharyngeal carcinoma during radiotherapy, and to ...
Detailed Description
Morphine controlled-release tablets and fentanyl transdermal patch each relieve radiation-induced oral mucositis pain in patients with nasopharyngeal carcinoma. But they do so by different mechanisms ...
Eligibility Criteria
Inclusion
- Patients were pathologically newly diagnosed with nasopharyngeal carcinoma and had no previous history of other tumors
- According to the treatment strategies of doctors, patients need to receive radiotherapy with or without chemotherapy (for example, neoadjuvant chemotherapy, concurrent chemotherapy, adjuvant chemotherapy) or targeted therapy
- Never use a opioid before treatment
- Hematology: WBC≥4.0×109/L, ANC≥1.5×109/L, PLT≥100×109/L,Hb≥90g/L.
- Participants with the ability to assess the pain level
- Willingness to return to enrolling institution for follow-up
Exclusion
- Patients do not conform to the inclusion criteria
- Known allergy to fentanyl, morphine, or any known component of the drug formulation
- Refuse to use of opioid drugs
- Nasopharyngeal patients with mental illness
- Current untreated or unresolved oral candidiasis or oral HSV infection
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Pregnant or Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Other contraindications or unsuitable conditions for radiotherapy
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04292990
Start Date
December 1 2020
End Date
December 1 2021
Last Update
July 29 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.